News
Bioiberica has followed a vertical integration strategy in the last three years towards the development and sale of finished products. All products undergo scientific and clinical development and have their own marketing strategy to support sales in each country.
Bioiberica Farma, the Spanish division of Bioiberica, has received approval for the combination of chondroitin and glucosamine in Spain. This is the first authorization of its kind in Europe.
Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
Bioiberica is going to held during 2010 in the three most important international conferences on diseases of the musculoskeletal system: those organized by EULAR, OARSI and ACR